Homepage IR Department newsroom

Compelling new lung disease treatment pioneered in Victoria gains global attention alongside top researchers and drug developers

Announcement posted by IR Department 21 Aug 2017

A novel drug treatment emerging from Victoria for the serious lung condition idiopathic pulmonary fibrosis will be spotlighted among world-leading researchers and scientists at the global IPF Summit in Boston (August 20-21).

Idiopathic pulmonary fibrosis (IPF) is a rare fibrotic lung condition that causes persistent and progressive scarring of the tiny air sacs (alveoli) in the lungs, with symptoms including shortness of breath and coughing[1]. Lung Foundation Australia estimate that there are around 2,300 new cases diagnosed in in Australia every year[2]. The prognosis of IPF is very poor, with a median survival of only three to five years after diagnosis.[3]

There are just two treatments on the market and the disease continues to progress in the majority of patients despite treatment.[4]
The new drug, AD-114, is being developed by the Australian biotech AdAlta (ASX:1AD), using AdAlta’s proprietary ‘i-body’ technology. A phase 1 clinical trial will start next year.

AD-114 differs from existing treatment options and others currently in clinical development due to its unique mode of action that targets the GPCR chemokine receptor CXCR4. AD-114 has been demonstrated to have both anti-inflammatory and anti-fibrotic activity, hitting a sweet spot for a potential therapy for IPF.

The effects of AD-114 have been described by world-leading lung disease researcher Professor Cory Hogaboam (Cedars Sinai Medical Centre) as “impressive” and “providing a compelling case” for treating IPF.

AdAlta CEO, Sam Cobb, has been invited to speak at the inaugural summit to showcase the novel therapeutic approach to this largely under-treated area. Ms Cobb will represent the only Australian company in the line-up of academics, international biotech and pharma speakers that include Prof Hogaboam as well as speakers from Genentech, Bristol-Myers Squibb, Celgene and Medimmune.

“IPF is a disease with high unmet clinical need and we do believe AD-114 will provide the clinical community and patients with a much-needed new treatment option,” Ms Cobb said.

“Although our focus with AD-114 is IPF, AD-114 has the potential to treat a wide-range of fibrotic conditions including wet age-related macular degeneration, of which there are 21,000 new cases diagnosed in Australia each year[5] and non-alcoholic fatty liver disease, which affects around 5.5 million Australians and is a precursor to nonalcoholic steatohepatitis (NASH)[6].
“That we’ve been invited to speak alongside world experts at the inaugural IPF Summit is immensely validating of the critical nature of our work.”

AD-114 has received orphan drug status by the FDA, and if approved would be a first-in-class treatment. ‘Orphan’ drugs are those developed to treat a rare medical condition, and they are usually granted accelerated development and regulatory timelines.

More about the IPF Summit: http://ipf-summit.com/
More about AdAlta: http://adalta.com.au/
***END***
 
More about AdAlta and its i-body technology:
AdAlta is an ASX listed Aussie biotech developing a new class of drugs to treat conditions with a high unmet clinical need.
AdAlta is pioneering antibody technology that it calls an ‘i-body’. The size and shape of an i-body gives it an advantage over typical and existing antibody therapies, because it can penetrate and bind to a diverse range of therapeutically-relevant targets. An i-body can also survive extreme conditions.  It can be boiled, dropped in acid, (other examples) and yet it remains stable and usable.
An i-body, with its long binding loop, is able to target the GPCR chemokine receptor CXCR4, making it applicable to treat a range of clinical conditions including fibrosis. AD-114 is AdAlta’s lead i-body candidate for the treatment of fibrosis.




Ilona Marchetta, Media and Digital Specialist @ IR Department
+61 416 156 136 | Level 14, 88 Pitt St, Sydney  NSW  2000 | www.irdepartment.com.au
Investor and public relations | marketing | corporate and crisis communications
 
About us: IR Department is a boutique investor relations consultancy based in Sydney, specialising in supporting small cap ASX listed companies with their engagement and communication with capital market participants.
 
 
[1] Lung Foundation Australia [online] at http://lungfoundation.com.au/health-professionals/idiopathic-pulmonary-fibrosis-registry/ [accessed 3 August 2017]
[2] Lung Foundation Australia [online] at http://lungfoundation.com.au/patient-support/rarelung/idiopathic-pulmonary-fibrosis-ipf/ [accessed 3 August 2017]
[3] ATS, 2000; Raghu et al., 2011
[4] Tzouvelekis A, Bonella F, Spagnolo P, ‘Update on Therapeutic Management of Idiopathic Pulmonary Fibrosis’, Therapeutics and Clinical Risk Management, 2015 Mar 3;11:359-70. doi: 10.2147/TCRM.S69716. eCollection 2015
[5] Macular Degeneration Foundation [online] at https://www.mdfoundation.com.au/sites/default/files/MDBooklet_2017-04_WEB.pdf [accessed 7 August 2017]
[6] The Economic Cost and Health Burden of Liver Disease in Australia (Jan 2013), Gastroenterological Society of Australia)

Media Contacts

Ilona Marchetta

Digital media and public relations specialist

Additional Resources

Company image


Download our logo

Attachments